ENTO (Entero Therapeutics) Short-Term Debt to Capital

Entero Therapeutics, Inc. (ENTO) integrates sustainability principles into the development of gastrointestinal therapies by reducing toxic emissions during synthesis. The business model relies on outsourcing production cycles and clinical trials to third-party contractors to optimize drug advancement. The current metric stands at 0.01, which is clearly confirmed by the price action on the chart illustrating the ratio of short-term liabilities to equity.

This indicator measures the ratio of liabilities with a maturity of over one year to equity, allowing for an assessment of long-term financial stability and the risk of excessive leverage. Analyzing the structure of short-term liabilities relative to equity helps determine the asset safety margin, which is critically important for Entero Therapeutics, Inc. (ENTO), whose stable revenue from the sale of gastrointestinal drugs ensures reliable debt service.